MYGN Q2 2025 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q2 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$213M+0.8% YoY

Gross Profit

$152M71.2% margin

Operating Income

-$329M-154.5% margin

Net Income

-$331M-155.1% margin

EPS (Diluted)

$-3.57

QoQ Revenue Growth

+8.8%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$21M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$677M

Total Liabilities

$289M

Stockholders' Equity

$388M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$213M	$212M	+0.8%
Gross Profit	$152M	$147M	+3.2%
Operating Income	-$329M	-$37M	-801.9%
Net Income	-$331M	-$37M	-800.5%

Geographic Segments

UNITED STATES

$198M93%

Non-US

$15M7%